Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week .


No.	Divisions/Titles for Abstract	Details
1	Abstract Title	Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets.
2	Abstract Source	Br J Nutr, 104, 1688-95.
3	Abstract Author(s)	Ono, T., Murakoshi, M., Suzuki, N., Iida, N., Ohdera, M., Iigo, M., Yoshida, T., Sugiyama, K. & Nishino, H.
4	Article Affiliation	Research and Development Headquarters, Lion Corporation, Odawara, Kanagawa, Japan. tomoono@lion.co.jp.
5	Abstract	Lactoferrin (LF), a multifunctional glycoprotein in mammalian milk, is reported to exert a modulatory effect on lipid metabolism. The aim of the present study was to elucidate whether enteric-coated LF (eLF) might improve visceral fat-type obesity, an underlying cause of the metabolic syndrome. Using a double-blind, placebo-controlled design, Japanese men and women (n 26; aged 22-60 years) with abdominal obesity (BMI>25 kg/m2, and visceral fat area (VFA)>100 cm2) consumed eLF (300 mg/d as bovine LF) or placebo tablets for 8 weeks. Measurement of the total fat area, VFA and subcutaneous fat area from computed tomography images revealed a significant reduction in VFA ( - 14.6 cm2) in the eLF group, as compared with the placebo controls ( - 1.8 cm2; P = 0.009 by ANCOVA). Decreases in body weight, BMI and hip circumference in the eLF group ( - 1.5 kg, - 0.6 kg/m2, - 2.6 cm) were also found to be significantly greater than with the placebo (+1.0 kg, +0.3 kg/m2, - 0.2 cm; P = 0.032, 0.013, 0.041, respectively). There was also a tendency for a reduction in waist circumference in the eLF group ( - 4.4 cm) as compared with the placebo group ( - 0.9 cm; P = 0.073). No adverse effects of the eLF treatment were found with regard to blood lipid or biochemical parameters. From these results, eLF appears to be a promising agent for the control of visceral fat accumulation.
6	Summary	-
7	Article Published Date	2010.
8	Study Type	A double-blind, placebo-controlled design.
9	Substances	Colostrum.
10	Diseases	Obesity.
11	Pharmacological Actions	Treatment of Obesity.
12	Link	https://goo.gl/6UPS56